180 related articles for article (PubMed ID: 8651712)
1. Long-term safety of cyclosporine in the treatment of psoriasis.
Grossman RM; Chevret S; Abi-Rached J; Blanchet F; Dubertret L
Arch Dermatol; 1996 Jun; 132(6):623-9. PubMed ID: 8651712
[TBL] [Abstract][Full Text] [Related]
2. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.
Ho VC; Griffiths CE; Berth-Jones J; Papp KA; Vanaclocha F; Dauden E; Beard A; Puvanarajan L; Paul C
J Am Acad Dermatol; 2001 Apr; 44(4):643-51. PubMed ID: 11260540
[TBL] [Abstract][Full Text] [Related]
3. [Renal function during long-term cyclosporin treatment of psoriasis].
Kaoukhov A; Paul C; Lahfa M; Blanchet F; Dubertret L
Ann Dermatol Venereol; 2000 Feb; 127(2):180-3. PubMed ID: 10739977
[TBL] [Abstract][Full Text] [Related]
4. Prolonged cyclosporine treatment of severe or recalcitrant psoriasis: descriptive study in a series of 20 patients.
Borghi A; Corazza M; Mantovani L; Bertoldi AM; Giari S; Virgili A
Int J Dermatol; 2012 Dec; 51(12):1512-6. PubMed ID: 23171021
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases.
Feutren G; Mihatsch MJ
N Engl J Med; 1992 Jun; 326(25):1654-60. PubMed ID: 1588978
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine: what clinicians need to know.
Koo J; Lee J
Dermatol Clin; 1995 Oct; 13(4):897-907. PubMed ID: 8785893
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
White M; Pelletier GB; Tan A; Jesina C; Carrier M
J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis.
Landewe RB; Goei The HS; van Rijthoven AW; Rietveld JR; Breedveld FC; Dijkmans BA
J Rheumatol; 1994 Sep; 21(9):1631-6. PubMed ID: 7799340
[TBL] [Abstract][Full Text] [Related]
9. Independent predictors of renal dysfunction after heart transplantation in patients with normal pretransplant renal function.
Garrido IP; Crespo-Leiro MG; Paniagua MJ; Muñiz J; Vázquez-Rey E; Pérez-Fernández R; García-Lara J; Cuenca-Castillo JJ; Castro-Beiras A
J Heart Lung Transplant; 2005 Sep; 24(9):1226-30. PubMed ID: 16143237
[TBL] [Abstract][Full Text] [Related]
10. The natural history of renal function following orthotopic heart transplant.
Al Aly Z; Abbas S; Moore E; Diallo O; Hauptman PJ; Bastani B
Clin Transplant; 2005 Oct; 19(5):683-9. PubMed ID: 16146562
[TBL] [Abstract][Full Text] [Related]
11. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease.
Sternthal MB; Murphy SJ; George J; Kornbluth A; Lichtiger S; Present DH
Am J Gastroenterol; 2008 Apr; 103(4):937-43. PubMed ID: 18177449
[TBL] [Abstract][Full Text] [Related]
12. Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use.
Behnam SM; Behnam SE; Koo JY
J Drugs Dermatol; 2005; 4(2):189-94. PubMed ID: 15776776
[TBL] [Abstract][Full Text] [Related]
13. Renal effects of maintenance low-dose cyclosporin A treatment in psoriasis.
Svarstad E; Helland S; Morken T; Bostad L; Myking A; Iversen BM; Ofstad J
Nephrol Dial Transplant; 1994; 9(10):1462-7. PubMed ID: 7816261
[TBL] [Abstract][Full Text] [Related]
14. Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study.
Lerut JP; Ciccarelli O; Mauel E; Gheerardhyn R; Talpe S; Sempoux C; Laterre PF; Roggen FM; Van Leeuw V; Otte JB; Gianello P
Transpl Int; 2001 Dec; 14(6):420-8. PubMed ID: 11793040
[TBL] [Abstract][Full Text] [Related]
15. Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy.
Ellis CN; Fradin MS; Hamilton TA; Voorhees JJ
Arch Dermatol; 1995 Jul; 131(7):791-5. PubMed ID: 7611794
[TBL] [Abstract][Full Text] [Related]
16. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
[TBL] [Abstract][Full Text] [Related]
17. Can maintenance cyclosporine be used in psoriasis without decreasing renal function?
Silverman AK; Emmett M; Menter A
Semin Dermatol; 1992 Dec; 11(4):302-12. PubMed ID: 1493094
[TBL] [Abstract][Full Text] [Related]
18. [Cyclosporine and psoriasis: experience with 14 patients].
Gajardo J
Rev Med Chil; 1993 Dec; 121(12):1411-5. PubMed ID: 8085065
[TBL] [Abstract][Full Text] [Related]
19. Experience of FK506 immune suppression in pediatric heart transplantation: a study of long-term adverse effects.
Asante-Korang A; Boyle GJ; Webber SA; Miller SA; Fricker FJ
J Heart Lung Transplant; 1996 Apr; 15(4):415-22. PubMed ID: 8732602
[TBL] [Abstract][Full Text] [Related]
20. Individual pharmacodynamics assessed by antilymphocyte action predicts clinical cyclosporine efficacy in psoriasis.
Hirano T; Oka K; Umezawa Y; Hirata M; Oh-i T; Koga M
Clin Pharmacol Ther; 1998 Apr; 63(4):465-70. PubMed ID: 9585801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
